Compare ADMA Biologics Inc (ADMA) vs AST SpaceMobile Inc (ASTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs AST SpaceMobile Inc — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while AST SpaceMobile Inc trades at $73.77 (market cap $22.17B). The key difference: AST SpaceMobile Inc is far larger — about 10.4× ADMA Biologics Inc's market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ASTS | |
|---|---|---|
Market Cap | $2.13B | $22.17B |
Sector | Health | Media |
52-Week High | $20.38 | $133.09 |
52-Week Low | $7.60 | $36.91 |
Enterprise Value | $2.20B | $22.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AST SpaceMobile (ASTS) trades at $74.21, down 12.83% in the last session amid a broader space stock selloff. The stock shows bearish technical signals with negative earnings surprises and deeply negative profitability margins. Recent news highlights satellite launch progress and competitive pressures from SpaceX, while cash flow remains heavily dependent on financing activities to fund operations and capital expenditures.
Outlook remains speculative with high execution risk; revenue growth is overshadowed by persistent losses and cash burn. Analyst consensus is mixed with a $84 price target offering potential upside, but investors face significant dilution risk and competitive threats in the nascent satellite broadband market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →
